West Nile Virus

Acambis is First Company to Test a West Nile Virus Vaccine in Older Adults

Published in Vaccine Weekly, April 4th, 2007

Acambis plc (Acambis) (LSE: ACM) announces that clinical testing of its investigational West Nile virus vaccine, ChimeriVax(TM)-West Nile, is underway in older adults, those most in need of protection against West Nile virus infection. Acambis' ChimeriVax-West Nile is the most advanced West Nile virus vaccine in development and the first to be tested in older adults.

According to the Centers for Disease Control and Prevention, people over the age of 50 are more likely to develop serious symptoms from West Nile virus infection; however, individuals of all ages living in areas where West Nile virus has been identified are at risk. West Nile virus continues to be a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2007-04-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry